<DOC>
	<DOC>NCT01498120</DOC>
	<brief_summary>This is a Phase 2, multicenter, open-label, single-arm, optimal dose, long-term follow-up study of monotherapy administration of rotigotine transdermal patch in adolescents with Restless Legs Syndrome (RLS). This study will assess the long-term safety and tolerability of Rotigotine treatment in adolescents with RLS.</brief_summary>
	<brief_title>Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome</brief_title>
	<detailed_description>Study design was changed and an amendment was prepared accordingly.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Tolerated the first dose level of Rotigotine in a previous study in adolescents with Restless Legs Syndrome (RLS), without meeting withdrawal criteria Is expected to benefit from participation, in the opinion of the investigator Subject/legal representative is considered reliable and capable of adhering to the protocol, visit schedule, and study patch application/removal, according to the judgment of the investigator Previously participated in this study Is experiencing an ongoing serious adverse event (SAE) that is assessed to be related to Rotigotine by the investigator or sponsor Pregnant or nursing or is a female of childbearing potential who is not surgically sterile or does not consistently use 2 combined medically acceptable methods of birth control (including at least 1 barrier method), unless not sexually active Any medical or psychiatric condition that, in the opinion of the investigator, can jeopardize or would compromise the subject's ability to participate Active suicidal ideation as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Since the Last Visit" version of the Columbia Suicide Severity Rating Scale (CSSRS) of the final evaluation visit of the previous Rotigotine study</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>RLS</keyword>
	<keyword>Long-term</keyword>
	<keyword>Adolescents</keyword>
</DOC>